| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
Form 4: Saxonov Serge, Director
Sold 31,000 shares ($1.95M) |
| 06 Nov 2026 |
Form 3: Satpathy Ansuman, Director
No securities owned |
| 06 Nov 2026 |
Form 3: Gilliam Joseph E, Director
Holds 31 shares of Class A Common Stock |
| 06 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
PLEASANTON, Calif. November 5, 2026 – 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the third quarter ended September... |
| 02 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 28, 2026, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Ansuman Satpathy and Joseph Gilliam to the Board of Directors as Cl... |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 24 Sep 2026 |
Form 4: Suliman Shehnaaz, Director
Sold 5,723 shares ($465K) |
| 24 Sep 2026 |
Form 4: Saxonov Serge, Director
Sold 25,000 shares ($2.03M) |
| 22 Sep 2026 | 144 |
| 11 Sep 2026 |
Form 4: Taich Adam, Chief Financial Officer
Sold 46,388 shares ($3M) |
| 09 Sep 2026 | 144 |
| 08 Sep 2026 |
Form 4: Stuelpnagel John R, Director
Sold 20,000 shares ($1.24M) |
| 08 Sep 2026 | SCHEDULE 13G |
| 03 Sep 2026 |
Form 4: Saxonov Serge, Director
Gave 100 shares as a gift |
| 03 Sep 2026 | 144 |
| 28 Aug 2026 |
Form 4: Saxonov Serge, Director
Sold 10,486 shares ($668K) |
| 26 Aug 2026 | 144 |
| 26 Aug 2026 |
Form 4: Saxonov Serge, Director
Sold 18,545 shares ($1.17M) |
Loading...